Nuvectis Pharma, Inc. Operating Income
Nuvectis Pharma, Inc. (NVCT) reported Operating Income of -$7.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Nuvectis Pharma, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$7.20M.
- Nuvectis Pharma, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$6.26M.
- Nuvectis Pharma, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$7.62M.
- Nuvectis Pharma, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$7.79M.
- Nuvectis Pharma, Inc. operating income (loss) for fiscal 2025 was -$27.57M.
- Nuvectis Pharma, Inc. operating income (loss) for fiscal 2024 was -$19.85M.
- Nuvectis Pharma, Inc. operating income (loss) for fiscal 2023 was -$22.90M.
- Nuvectis Pharma, Inc. operating income (loss) for fiscal 2022 was -$19.23M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.20M 10-Q · filed 2026-08-04 | -$13.46M 10-Q · filed 2026-08-04 | -$21.07M derived: sum of 3 quarters · filed 2026-08-04 | -$28.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$6.26M 10-Q · filed 2026-05-05 | -$13.88M derived: sum of 2 quarters · filed 2026-05-05 | -$21.67M derived: sum of 3 quarters · filed 2026-05-05 | -$28.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$15.41M derived: sum of 2 quarters · filed 2026-02-11 | -$22.01M derived: sum of 3 quarters · filed 2026-08-04 | -$27.57M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$7.79M 10-Q · filed 2025-11-04 | -$14.39M derived: sum of 2 quarters · filed 2026-08-04 | -$19.96M 10-Q · filed 2025-11-04 | -$26.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$6.59M 10-Q · filed 2026-08-04 | -$12.16M 10-Q · filed 2026-08-04 | -$18.61M derived: sum of 3 quarters · filed 2026-08-04 | -$22.97M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$5.57M 10-Q · filed 2026-05-05 | -$12.02M derived: sum of 2 quarters · filed 2026-05-05 | -$16.38M derived: sum of 3 quarters · filed 2026-05-05 | -$21.02M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$10.81M derived: sum of 2 quarters · filed 2026-02-11 | -$15.45M derived: sum of 3 quarters · filed 2026-02-11 | -$19.85M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$4.36M 10-Q · filed 2025-11-04 | -$9.00M derived: sum of 2 quarters · filed 2025-11-04 | -$13.40M 10-Q · filed 2025-11-04 | -$20.26M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$4.64M 10-Q · filed 2025-08-05 | -$9.04M 10-Q · filed 2025-08-05 | -$15.90M derived: sum of 3 quarters · filed 2025-08-05 | -$22.06M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$4.40M 10-Q · filed 2025-05-06 | -$11.26M derived: sum of 2 quarters · filed 2025-05-06 | -$17.42M derived: sum of 3 quarters · filed 2025-05-06 | -$23.19M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$13.02M derived: sum of 2 quarters · filed 2025-02-25 | -$18.80M derived: sum of 3 quarters · filed 2025-02-25 | -$22.90M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$6.16M 10-Q · filed 2024-11-05 | -$11.93M derived: sum of 2 quarters · filed 2024-11-05 | -$16.03M 10-Q · filed 2024-11-05 | -$22.81M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$5.77M 10-Q · filed 2024-08-06 | -$9.87M 10-Q · filed 2024-08-06 | -$16.65M derived: sum of 3 quarters · filed 2024-08-06 | -$22.59M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$4.10M 10-Q · filed 2024-05-07 | -$10.88M derived: sum of 2 quarters · filed 2024-05-07 | -$16.82M derived: sum of 3 quarters · filed 2024-05-07 | -$20.39M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$12.72M derived: sum of 2 quarters · filed 2024-03-05 | -$16.29M derived: sum of 3 quarters · filed 2024-03-05 | -$19.23M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$5.94M 10-Q · filed 2023-11-08 | -$9.51M derived: sum of 2 quarters · filed 2023-11-08 | -$12.46M 10-Q · filed 2023-11-08 | -$14.72M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$3.57M 10-Q · filed 2023-08-09 | -$6.52M 10-Q · filed 2023-08-09 | -$8.78M derived: sum of 3 quarters · filed 2023-08-09 | -$13.45M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$2.94M 10-Q · filed 2023-05-10 | -$5.21M derived: sum of 2 quarters · filed 2023-05-10 | -$9.88M derived: sum of 3 quarters · filed 2023-05-10 | -$15.82M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$6.93M derived: sum of 2 quarters · filed 2023-03-08 | -$12.87M derived: sum of 3 quarters · filed 2023-03-08 | -$12.89M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$4.67M 10-Q · filed 2022-11-08 | -$10.61M derived: sum of 2 quarters · filed 2022-11-08 | -$10.63M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$5.94M 10-Q · filed 2022-08-10 | -$5.96M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | -$23.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |